| Today's Big NewsJan 9, 2023 |
|
Thursday, January 19, 2023 | 11:00am ET In this webinar, hear how Novartis uses social data from public forums worldwide to understand the educational and emotional needs of patients with Myelodysplastic Syndromes (MDS), and thereby create more targeted solutions to meet these needs. Register now. 
|
|
| By Kevin Dunleavy How did Moderna perform with sales of its COVID-19 vaccine in 2022? On Monday, the mRNA juggernaut reported that Spikevax generated approximately $18.4 billion in revenue. The number was short of the company’s original estimate of $22 billion at the start of the year but did exceed its 2021 sales of $17.7 billion. The company is sticking to its previous projection of $5 billion for 2023, while revealing it will spend $4.5 billion on R&D this year. |
|
|
|
By Annalee Armstrong The markets battered biotechs in 2022, even those that had the backing of Moderna's venture capital firm Flagship Pioneering. But good science takes time, CEO Noubar Afeyan wrote in a letter to shareholders. |
By Dave Muoio A total 16,000 nurses working in eight New York City hospitals had voted to authorize a walk-off, though more than half have come to terms with their hospitals. Mount Sinai Medical Center and Montefiore Medical Center said they are rescheduling appointments and elective procedures but will keep their hospitals open. |
By Conor Hale With sums described as estimates ahead of the company’s full disclosure slated for Feb. 1, Hologic reported that the final three months of 2022 brought in a total of $1.07 billion in sales. |
|
Tuesday, January 24, 2023 | 11am ET / 8am PT Your CRO is a finalist in a project bid and clinical supplies are one of the aspects that you will manage on behalf of the client via a partner. Register now. 
|
|
By Nick Paul Taylor AstraZeneca has kicked off the J.P.Morgan Healthcare Conference with a deal, capitalizing on the recent collapse of CinCor Pharma’s share price to snap up the blood pressure biotech in a $1.8 billion deal. |
By Kevin Dunleavy Bristol Myers Squibb has come up short in its last-ditch effort to get the U.S. Supreme Court to review its decision from two months ago. Pfizer also suffered a defeat at the High Court. |
By Frank Diamond The Federal Trade Commission yesterday proposed a rule that would essentially do away with noncompete agreements. Most U.S. industries would be affected, including healthcare. |
By Conor Hale The AI-powered drug designer Schrödinger is growing its to-do list, with two Big Pharma collaborations focused in neuroscience. |
By Ben Adams Eisai nabbed an accelerated FDA approval last week for its new Alzheimer’s drug, and we now have a new entry into the drug name world in Leqembi. |
By Gabrielle Masson Eli Lilly’s plate is full this year, CMO says from the sidelines of the J.P. Morgan Healthcare conference, with five potential launches cooking and 10 top priorities. |
By Heather Landi About six months after cutting 8% of its global workforce, hybrid primary care company Carbon Health announced on Friday another round of layoffs and corporate restructuring efforts. |
By Andrea Park In its first days as a standalone company, GE HealthCare has already hit the ground running. |
By Eric Sagonowsky Before bluebird bio nabbed a pair of gene therapy FDA approvals for last summer, the company’s future looked uncertain. Entering 2023, the gene therapy specialist at least has a commercial business to build. |
By Annalee Armstrong Editas is taking the red pen to its pipeline after a tough 2022 that saw the gene editing biotech cut a lead asset due to disappointing data—and the changes are going to mean more than a little rewrite. |
By Heather Landi,Paige Minemyer All the latest healthcare and health tech news from the J.P. Morgan Healthcare Conference in San Francisco. |
By Conor Hale Claria Medical aims to deliver a medical device that turns the removal of the uterus into a minimally invasive, laparoscopic procedure. |
Fierce podcasts Don't miss an episode |
| This week on “The Top Line,” we discuss the biotech industry’s rotten tomatoes. Plus, we cover the drug approvals of last year, a congressional report on Biogen's "inappropriate" communications with the FDA and other top headlines from this week. |
|
|---|
|
|
|
Tuesday, January 24, 2023 | 11am ET / 8am PT UGTs are the most common enzymes involved in metabolism after CYP enzymes, followed by numerous hydrolases, carbonyl reductases, aldehyde oxidase and other enzymes. Hear Dr. Brian Ogilvie discuss case studies and strategies to address non-CYP related metabolism questions in your drug’s safety assessment. Register now. 
|
|
Whitepaper This paper explores how Medical Affairs is adapting medical communications to meet the demands of a new environment (part 5 in a series). Sponsored by: Blue Matter, strategic consultants in the life sciences |
On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
Executive Summary Readers will learn manufacturing by Design Builds on Quality by Design, De-risking the Tech Transfer Process, and more. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
Whitepaper Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
Whitepaper Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| |
|
